Sterman D H, Kaiser L R, Albelda S M
Department of Medicine, University of Pennsylvania Health System, Philadelphia, USA.
Hematol Oncol Clin North Am. 1998 Jun;12(3):553-68. doi: 10.1016/s0889-8588(05)70008-3.
Malignant mesothelioma (MM) is a fatal malignancy refractory to all forms of standard anticancer therapy. This article reports the results of a phase I clinical trial assessing the safety of intrapleural delivery and efficacy of intratumoral gene transfer of recombinant adenovirus (rAd) containing herpes simplex virus thymidine kinase (HSVtk) gene into the pleural space of patients with MM, followed by systematic treatment with the antiviral drug ganciclovir (GCV) for 14 days. AD.RSVtk/GCV gene therapy proved to be well tolerated, with evidence of significant gene transfer particularly at high vector doses and with elimination of preliminary biopsy. Ongoing gene therapy trials for mesothelioma at two other centers, focusing on immunostimulation and using suicide gene therapy as a tumor vaccine, are also reviewed in this article.
恶性间皮瘤（MM）是一种对所有标准抗癌治疗均具有耐药性的致命性恶性肿瘤。本文报告了一项I期临床试验的结果，该试验评估了将含有单纯疱疹病毒胸苷激酶（HSVtk）基因的重组腺病毒（rAd）经胸膜腔内给药的安全性以及向MM患者胸膜腔进行瘤内基因转移的疗效，随后用抗病毒药物更昔洛韦（GCV）进行为期14天的全身治疗。AD.RSVtk/GCV基因治疗耐受性良好，尤其在高载体剂量时存在显著基因转移的证据，且无需进行初步活检。本文还综述了另外两个中心正在进行的针对间皮瘤的基因治疗试验，这些试验聚焦于免疫刺激并将自杀基因治疗用作肿瘤疫苗。
